参考文献 References
[1] Giordano A, Tommonaro G. Curcumin and Cancer. Nutrients. Oct 2019;11(10).
[2] Weng W, Goel A. Curcumin and colorectal cancer: An update and current perspective on this natural medicine. Semin Cancer Biol. May 2022;80:73-86.
[3] Tomeh MA, Hadianamrei R, Zhao X. A Review of Curcumin and Its Derivatives as Anticancer Agents. Int J Mol Sci. Feb 27 2019;20(5).
[4] Vallee A, Lecarpentier Y, Guillevin R, Vallee JN. Opposite Interplay Between the Canonical WNT/beta-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas. Neurosci Bull. Jun 2018;34(3):573-588.
[5] Ghasemi F, Shafiee M, Banikazemi Z, et al. Curcumin inhibits NF-kB and Wnt/beta-catenin pathways in cervical cancer cells. Pathol Res Pract. Oct 2019;215(10):152556.
[6] Wu MF, Huang YH, Chiu LY, Cherng SH, Sheu GT, Yang TY. Curcumin Induces Apoptosis of Chemoresistant Lung Cancer Cells via ROS-Regulated p38 MAPK Phosphorylation. Int J Mol Sci. Jul 26 2022;23(15).
[7] Zhang MJ, Shi M, Yu Y, Wang H, Ou R, Ge RS. CP41, a novel curcumin analogue, induces apoptosis in endometrial cancer cells by activating the H3F3A/ proteasome-MAPK signaling pathway and enhancing oxidative stress. Life Sci. Feb 1 2024;338:122406.
[8] Chien MH, Shih PC, Ding YF, et al. Curcumin analog, GO-Y078, induces HO-1 transactivation-mediated apoptotic cell death of oral cancer cells by triggering MAPK pathways and AP-1 DNA-binding activity. Expert Opin Ther Targets. Apr 2022;26(4):375-388.
[9] He Q, Liu C, Wang X, et al. Exploring the mechanism of curcumin in the treatment of colon cancer based on network pharmacology and molecular docking. Front Pharmacol. 2023;14:1102581.
[10] Meena R, Kumar S, Kumar R, Gaharwar US, Rajamani P. PLGA-CTAB curcumin nanoparticles: Fabrication, characterization and molecular basis of anticancer activity in triple negative breast cancer cell lines (MDA-MB-231 cells). Biomed Pharmacother. Oct 2017;94:944-954.
[11] Li W, Sun L, Lei J, Wu Z, Ma Q, Wang Z. Curcumin inhibits pancreatic cancer cell invasion and EMT by interfering with tumor‑stromal crosstalk under hypoxic conditions via the IL‑6/ERK/NF‑kappaB axis. Oncol Rep. Jul 2020;44(1):382-392.
[12] Li M, Guo T, Lin J, et al. Curcumin inhibits the invasion and metastasis of triple negative breast cancer via Hedgehog/Gli1 signaling pathway. J Ethnopharmacol. Jan 30 2022;283:114689.
[13] Bulboaca AE, Porfire A, Bolboaca SD, et al. Protective Effects of Liposomal Curcumin on Oxidative Stress/Antioxidant Imbalance, Metalloproteinases 2 and -9, Histological Changes and Renal Function in Experimental Nephrotoxicity Induced by Gentamicin. Antioxidants (Basel). Feb 22 2021;10(2).
[14] SoukhakLari R, Moezi L, Pirsalami F, Moosavi M. The Effect of BSA-Based Curcumin Nanoparticles on Memory and Hippocampal MMP-2, MMP-9, and MAPKs in Adult Mice. J Mol Neurosci. Jul 2018;65(3):319-326.
[15] Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms Controlling PD-L1 Expression in Cancer. Mol Cell. Nov 7 2019;76(3):359-370.
[16] Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer. Jan 21 2022;21(1):28.
[17] Gou Q, Dong C, Xu H, et al. PD-L1 degradation pathway and immunotherapy for cancer. Cell Death Dis. Nov 6 2020;11(11):955.
[18] Zhang M, Wang L, Liu W, et al. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors. J Immunol Res. 2022;2022:2253436.
[19] Tang X, Yang J, Shi A, et al. CD155 Cooperates with PD-1/PD-L1 to Promote Proliferation of Esophageal Squamous Cancer Cells via PI3K/Akt and MAPK Signaling Pathways. Cancers (Basel). Nov 15 2022;14(22).
[20] Messeha SS, Zarmouh NO, Soliman KFA. Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer. Nutrients. May 19 2021;13(5).
[21] Shen M, Xu Z, Xu W, et al. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway. J Exp Clin Cancer Res. Apr 8 2019;38(1):149.
[22] Hayakawa T, Yaguchi T, Kawakami Y. Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT3. Cancer Sci. Dec 2020;111(12):4326-4335.
[23] Yang YSH, Li ZL, Shih YJ, et al. Herbal Medicines Attenuate PD-L1 Expression to Induce Anti-Proliferation in Obesity-Related Cancers. Nutrients. Dec 52019;11(12).
[24] Zanotelli MR, Zhang J, Reinhart-King CA. Mechanoresponsive metabolism in cancer cell migration and metastasis. Cell Metab. Jul 6 2021;33(7):1307-1321.
[25] Ou D, Wu Y, Zhang J, et al. miR-340-5p affects oral squamous cell carcinoma (OSCC) cells proliferation and invasion by targeting endoplasmic reticulum stress proteins. Eur J Pharmacol. Apr 5 2022;920:174820.
[26] Wang F, Zhang H, Cheng Z. EPHA2 Promotes the Invasion and Migration of Human Tongue Squamous Cell Carcinoma Cal-27 Cells by Enhancing AKT/mTOR Signaling Pathway. Biomed Res Int. 2021;2021:4219690.
[27] Huang B, Wu C, Hu Y, et al. Osmanthus-Loaded PVP/PVA Hydrogel Inhibits the Proliferation and Migration of Oral Squamous Cell Carcinoma Cells CAL-27. Polymers (Basel). Dec 9 2022;14(24).
[28] Tchegnitegni B T, Ahmed T, Ngouafong F T, et al. Echinocystic Acid Bidesmoside Saponins from Microglossa afzelii O. Hoffm and Their Cytotoxic Activity against the CAL-27 Oral Squamous Carcinoma Cell Line. Metabolites. 2022;12(11):1018.
[29] Brockmueller A, Ruiz de Porras V, Shakibaei M. Curcumin and its anti-colorectal cancer potential: From mechanisms of action to autophagy. Phytother Res. May 32024.
[30] Kong D, Zhang Z, Chen L, et al. Curcumin blunts epithelial-mesenchymal transition of hepatocytes to alleviate hepatic fibrosis through regulating oxidative stress and autophagy. Redox Biol. Sep 2020;36:101600.
[31] Guo L, Li H, Fan T, Ma Y, Wang L. Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma. Life Sci. Aug 15 2021;279: 119359.
[32] Xu L, Zhang Y, Tian K, et al. Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects. J Exp Clin Cancer Res. Oct 29 2018;37(1):261.
[33] Liang J, Wang L, Wang C, et al. Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy. Cancer Immunol Res. Jul 2020;8(7):952-965.